首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DIT33 |
| Uniprot No | Q27384 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-234aa |
| 氨基酸序列 | SVINRHNKRFAGFSVAGIGGTAGCVVVDNKLFANSFYLRDLTTEEQRELAQYVEDSNQYKEEVKTSLEERRKGWQLARHGEKDAKVLSSLAEKKFPKPPKKPSFCSAGDTTQYYFDGCMVQNNKIYVGRMYVRDLTSDEINQLKTFDAKMTAYQKYLSSSIQQQVDSLFGDKSNLFNLFTDTRHETSSQPSDATTISTTTQAPVEPPETPHFCIAIY |
| 预测分子量 | 32.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于DIT33重组蛋白的假设性参考文献示例(注：DIT33为虚构蛋白代号，实际文献需根据具体研究领域检索)：
---
1. **文献名称**: "Cloning and Expression of Recombinant DIT33 Protein in E. coli"
**作者**: Zhang L., et al.
**摘要**: 本研究成功克隆了DIT33基因，并利用大肠杆菌表达系统高效表达可溶性重组蛋白。通过优化诱导条件及纯化工艺，获得了高纯度DIT33.为后续功能研究奠定基础。
2. **文献名称**: "Structural Characterization of DIT33 Recombinant Protein and Its Role in Cancer Cell Apoptosis"
**作者**: Patel R.K., et al.
**摘要**: 通过X射线晶体学解析DIT33重组蛋白的三维结构，并证实其通过激活p53通路诱导肿瘤细胞凋亡，提示其作为癌症治疗靶点的潜力。
3. **文献名称**: "DIT33 Recombinant Protein as a Novel Diagnostic Marker for Autoimmune Diseases"
**作者**: Tanaka S., et al.
**摘要**: 研究开发了基于DIT33重组蛋白的ELISA检测方法，发现其在类风湿关节炎患者血清中显著高表达，可作为新型自身免疫疾病生物标志物。
---
**说明**：若需真实文献，请提供DIT33蛋白的完整名称或相关研究领域(如肿瘤、免疫等)，以便精准检索。以上示例展示了重组蛋白研究中常见的克隆表达、结构功能、应用开发等方向。
DIT33 is a recombinant protein engineered for potential therapeutic and research applications, particularly in areas involving immune modulation and cellular signaling. As a recombinant protein, it is produced through genetic engineering techniques, where the encoding DNA sequence is inserted into a host system (e.g., bacterial, yeast, or mammalian cells) to enable large-scale expression. The "DIT33" designation likely refers to its specific molecular structure or target interaction, though detailed public data on its exact mechanism remains limited without context-specific studies.
Recombinant proteins like DIT33 are often designed to mimic or inhibit natural proteins involved in critical biological pathways. For instance, DIT33 may target cytokines, growth factors, or cell-surface receptors implicated in inflammatory diseases, autoimmune disorders, or cancer. Its development typically involves optimizing stability, bioavailability, and binding affinity through techniques like site-directed mutagenesis or fusion with stabilizing domains (e.g., Fc regions).
In biopharmaceutical contexts, such proteins undergo rigorous purification (e.g., affinity chromatography) and validation (e.g., ELISA, bioassays) to ensure functionality. Preclinical studies would assess its efficacy in disease models and toxicity profiles. If DIT33 aligns with trends in immunotherapy, it might act as a checkpoint inhibitor or cytokine analog to enhance immune responses against tumors or suppress overactive immunity.
Challenges in developing DIT33 could include ensuring proper post-translational modifications (e.g., glycosylation) for biological activity, minimizing immunogenicity, and achieving scalable production. Collaborations between academic labs and biotech firms often drive such innovations, with clinical potential hinging on early-phase trial outcomes. While specific details on DIT33 are sparse without targeted references, its framework exemplifies the broader pursuit of engineered proteins to address unmet medical needs. Further characterization would clarify its role in translational research or therapeutic pipelines.
×
